Qualigen Therapeutics Terminates Material Definitive Agreement
Ticker: AIXC · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1460702
| Field | Detail |
|---|---|
| Company | Qualigen Therapeutics, INC. (AIXC) |
| Form Type | 8-K |
| Filed Date | Mar 28, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, corporate-action
TL;DR
Qualigen terminated a key deal, expect news soon.
AI Summary
Qualigen Therapeutics, Inc. announced on March 25, 2024, the termination of a material definitive agreement. The company, formerly known as Ritter Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Carlsbad, California.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's strategic direction and financial obligations.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's future operations and financial stability.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- Ritter Pharmaceuticals Inc. (company) — Former company name
- March 25, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Principal executive offices location
FAQ
What was the specific material definitive agreement that was terminated?
The filing does not specify the details of the material definitive agreement that was terminated.
When did the termination of the agreement become effective?
The filing states that March 25, 2024, was the date of the earliest event reported, which is the termination of the agreement.
What are the potential consequences of this termination for Qualigen Therapeutics?
The filing does not detail the specific consequences, but termination of a material agreement can impact operations, finances, and strategic partnerships.
Is there any information about a replacement agreement or new strategic direction?
This filing does not contain information about a replacement agreement or a new strategic direction.
What was Qualigen Therapeutics' former name?
Qualigen Therapeutics, Inc. was formerly known as Ritter Pharmaceuticals Inc.
Filing Stats: 821 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-03-28 16:05:31
Key Financial Figures
- $1,000,000 — gs would have paid us an upfront fee of $1,000,000 in cash. In addition, Pan-RAS Holdings
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 12KB
- 0001493152-24-011732.txt ( ) — 223KB
- qlgn-20240325.xsd (EX-101.SCH) — 3KB
- qlgn-20240325_lab.xml (EX-101.LAB) — 33KB
- qlgn-20240325_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: March 28, 2024 By: /s/ Michael S. Poirier Michael S. Poirier, Chief Executive Officer